Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | GvHD highlights: use of biomarkers to guide treatment

Iskra Pusic • 17 Feb 2023
Tandem Meetings 2023
General

Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, shares some of the highlights in graft-versus-host disease (GvHD) that were presented at this year’s Tandem Meetings, drawing focus on the use of biomarkers to guide treatment. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Iskra Pusic

2:22
Determining how to optimally use FDA-approved drugs in chronic GvHD
Iskra Pusic • 17 Feb 2023
5:47
Use of belimumab for prophylaxis of chronic GvHD
Iskra Pusic • 24 Apr 2022
1:53
Advances and unmet needs in chronic GvHD
Iskra Pusic • 24 Apr 2022
4:21
Recent advances in the management of acute GvHD
Iskra Pusic • 22 Sep 2021

Related Videos

1:46
Assessing PFS and alternative endpoints for advanced cancer clinical trials
Jurjen Versluis • 22 Apr 2024
1:15
Reducing steroid usage in the treatment of lower-risk GvHD
James Ferrara • 16 Apr 2024
1:02
The MAGIC model: a day 14 endpoint for acute GvHD clinical trials
James Ferrara • 16 Apr 2024
1:19
Mitigating the potential complications of CAR-T therapy: important supportive care measures
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals